Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-10
Target enrollment:
Participant gender:
Summary
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)
Phase:
NA
Details
Lead Sponsor:
Bioray Laboratories
Collaborator:
Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College